Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
about
The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.Incidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer
P2860
Q30749009-E45809D2-AC4E-4D35-AA8A-FD45A1F8D9E6Q33557215-D5D0140C-3C7B-4819-8A1F-79CD9001140EQ33718051-BAD874C3-5C0B-4A6D-8F4F-4A5BE212DF14Q34565988-A81C2385-9F21-4669-B6DC-7B82F58CF6A0Q34585066-832F3DBC-0536-4AFD-9063-B292C24F0504Q35044368-00B361D2-8EDC-49B2-AC8C-44E36EFEEED8Q36910461-B8632C12-F206-4CFB-89A3-74F2018FCD43Q37703409-E9D4289F-77BE-4487-921C-E85A9FAAE9A9Q43571500-4CEDC519-4282-4BAE-87FD-B3FB60BFB8FDQ44711105-9AD4B909-6761-4BB6-B512-9FB37C41A022Q54977541-3CC1D3E5-30B6-422D-BAD0-F428959E8728Q57152512-14D51BB6-687B-4F00-A4BB-0BAA448FDEA8
P2860
Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Neutropenia-related costs in p ...... ed non-small cell lung cancer.
@en
type
label
Neutropenia-related costs in p ...... ed non-small cell lung cancer.
@en
prefLabel
Neutropenia-related costs in p ...... ed non-small cell lung cancer.
@en
P2093
P1476
Neutropenia-related costs in p ...... ed non-small cell lung cancer.
@en
P2093
Catherine E Muehlenbein
Don P Buesching
Douglas E Faries
Joseph Lipscomb
Kevin B Knopf
Martin D Marciniak
Michael E Stokes
Saeed Motabar
Theresa W Gillespie
P304
P356
10.18553/JMCP.2009.15.8.669
P577
2009-10-01T00:00:00Z